Single subcutaneous injections of the siRNA, SLN360 (30 mg, 100 mg, 300 mg or 600 mg), which targets mRNA for the apolipoprotein(a) gene (LPA) have been shown to reduce Lp(a) levels by up to 98%.1 Initial data from the Phase 1 APOLLO study, presented by Dr Steve Nissen (Cleveland Clinic, Cleveland, Ohio), also showed that >70% and >80% reductions in Lp(a) persisted for 150 days after the 300 mg and 600 mg doses. The highest doses reduced LDL-C and ApoB by 20-30%. There were no major safety issues, although low-grade, transient, dose-dependent injection site reactions occurred. A multi-dose study is underway.
Reference
- Nissen SE. A single ascending dose study of an siRNA targeting lipoprotein(a). Presented at ACC.22, April 2-4 2022, Washington DC, USA, Late Breaker